Advertisement


Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

2024 ASCO Annual Meeting

Advertisement

Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We designed the study back in 2012. It was a study of metformin, men with active surveillance for prostate cancer, and there was a lot of rationales as to why metformin would be useful in prostate cancer. There's laboratory studies that we've done speaking to the importance of metformin inhibiting mTOR as well as having epigenetic effects. There's data from other groups looking at the beneficial effect of metformin on the tumor microenvironment. There's epidemiological studies that suggest that diabetic men who take metformin do better for their prostate cancer treatment. There's combination studies that we've done demonstrating that, in some of the pivotal prostate cancer studies, the men who took metformin did better in the studies with abiraterone. So we put all those things together. We thought, well, metformin may be the perfect medication to give men undergoing active surveillance of prostate cancer. So from the period of 2013 to 2023, we randomised 400 men, approximately 204 on each arm to take metformin versus a matched placebo when they were undergoing active surveillance. And active surveillance is briefly, as per NCCN, very low to low risk criteria. Basically men with low volume Gleason 6 disease, and there's more details in the presentation, but those men were randomised over that period, and the endpoint was defined as either being therapeutic progression or pathological progression. The pathological progression was biopsies done at 18 and 36 months, and their therapeutic progression was any treatment for prostate cancer. And in brief, we found no difference between the arms, and in fact, there was a couple of concerning trends. One trend was that men who had a high BMI actually seemed to do worse on metformin for reasons we don't understand. And a priori, you would think those men would do better on metformin because they may lose weight, but that was not the case. And also there seemed to be a slight trend towards men progressing with higher Gleason scores who took metformin compared to those men who took placebo. This is a little bit worrying, and certainly we need to do more research to understand why this is the case. But this study was an academic study across 12 centers in Canada, funded through, essentially philanthropy, the Prostate Cancer Foundation, and the Canadian Cancer Association. So taken together, I think this has been a great academic effort. It will seed a lot of future research to understand the role of metformin and those types of drugs in men with and without diabetes for prostate cancer undergoing active surveillance.

Related Videos

Breast Cancer

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy

Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for this population showed that using docetaxel as the preferred taxane may be beneficial (LBA503).

Skin Cancer

Pauline Funchain, MD and Paolo A. Ascierto, MD, on Advanced Melanoma: Results From the RELATIVITY-048 Trial

Pauline Funchain, MD, of Stanford University and the Stanford Cancer Institute, and Paolo A. Ascierto, MD, of Italy’s Istituto Nazionale Tumori and IRCCS Fondazione G. Pascale, discuss efficacy and safety findings of the triplet therapy nivolumab, relatlimab-rmbw, and ipilimumab in patients with advanced melanoma (Abstract 9504).

 

Leukemia
Lymphoma

Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses the ongoing phase III BELLWAVE-010 study of nemtabrutinib plus venetoclax vs venetoclax plus rituximab in previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (Abstract TPS7089).  

Skin Cancer

Georgina V. Long, MD, PhD, on BRAF-Mutated Melanoma: Long-Term Follow-up of Adjuvant Dabrafenib Plus Trametinib vs Placebo

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and The University of Sydney, discusses final results with up to 10 years’ follow-up data of the COMBI-AD study of patients with stage III BRAF-mutated melanoma who received adjuvant dabrafenib plus trametinib (Abstract 9500).

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).

 

Advertisement

Advertisement




Advertisement